A bill to require the Secretary of Health and Human Services to prepare a report that outlines a plan for completing a review of approved opioid analgesic drugs that considers the public health effects of such opioid drugs.

S 3557 requires the Secretary of Health and Human Services (through the FDA) to create a report within one year of enactment. The report must outline a plan for reviewing approved opioid pain medicines, specifically considering their public health impact in safety and effectiveness assessments. It also mandates including public input, FDA actions on opioid safety, a timeline for potential label changes or enforcement, and steps to support non-addictive pain treatment development. This bill directly affects the FDA's regulatory process for opioid drugs and its approach to pain medicine innovation. The focus is on structuring a transparent review process, not on mandating specific outcomes for opioids.